Focused On-demand Library for RNA helicase aquarius

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O60306

UPID:

AQR_HUMAN

Alternative names:

Intron-binding protein of 160 kDa

Alternative UPACC:

O60306; A0JP17; A5YKK3; Q2YDX9; Q6IRU8; Q6PIC8

Background:

RNA helicase aquarius, also known as the Intron-binding protein of 160 kDa, plays a crucial role in pre-mRNA splicing as part of the spliceosome complex. It is essential for the linkage between pre-mRNA splicing and snoRNP biogenesis, facilitating the assembly of intron-encoded box C/D small snoRNP. Its ability to bind introns in a sequence-independent manner and its ATP-dependent RNA helicase activity underscore its importance in RNA processing.

Therapeutic significance:

Understanding the role of RNA helicase aquarius could open doors to potential therapeutic strategies. Its pivotal function in RNA processing and splicing mechanisms highlights its potential as a target for therapeutic intervention in diseases where these processes are dysregulated.